The 5-year survival rate of patients with stages I, II and III gastric cancer and weak MAP3K4 expression was significantly greater than that of those with strong MAP3K4 expression (P =0.0102; P < 0.0001; P < 0.0001, respectively) (Fig. 12). Here, MAP3K4 is linked to gastric cancer.